Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 38
Healthy volunteers: no

Brief summary:
The primary purpose of this Study is to help answer the following research question(s).

* How does LY2189265 affect gastric emptying (the speed at which food and drink leaves the stomach) in patients with Type 2 diabetes?
* How does LY2189265 affect how the body handles metformin (a drug used to treat Type 2 diabetes)?
* Is LY2189265 safe and are any side effects associated with it?

The study will be participant-blind in Week 1, and participant- and investigator-blind from Week 2 through Week 5.

Each participant will receive placebo on Week 1 and once-weekly doses of LY2189265 or Placebo on Weeks 2 to 5. Participants taking metformin for the treatment of Type 2 Diabetes Mellitus (T2DM) will continue taking metformin as part of the study.

Detailed description:

Arms:
arm 1: Each participant will receive placebo on Week 1. Participants randomized to placebo will receive once-weekly doses of placebo on Weeks 2 to 5.

Placebo will be administered by single subcutaneous injection into the skin of the abdominal wall.

Participants regularly taking metformin will continue their normal dosing regimen throughout the study. arm 2: Participants randomized to LY2189265 will receive once-weekly doses of LY2189265 on Weeks 2 to 5.

1.5 milligram (mg) LY2189265 will be administered by single subcutaneous injection into the skin of the abdominal wall.

Participants regularly taking metformin will continue their normal dosing regimen throughout the study.

Interventions: intervention 1: LY2189265 intervention 2: Placebo
Intervention descriptions: intervention 1: 1.5 mg administered subcutaneously intervention 2: Administered subcutaneously

Protocol document: